Clinical trials: Stage III Skin Cancer
Melanoma
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
The purpose of this clinical trial is to evaluate the benefit of the immunotherapeutic product GSK 2132231A in preventing disease relapse when given to melanoma patients, after surgical removal of their tumor.
- Trial name
- NCT00796445
- Testing
- GSK 2132231A
- Where
- 257 sites in United States, Argentina and 30 more
- Volunteers
- 1,351 people
- Sponsor
- GlaxoSmithKline
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes.
- Conditions
- Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Trial name
- NCT04221438
- Testing
- Binimetinib, Conventional Surgery, Encorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
This randomized phase II trial studies how well fulvestrant works with or without bortezomib in treating patients with estrogen receptor positive breast cancer that has spread to other places in the body and cannot be removed by…
- Conditions
- Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT01142401
- Testing
- Bortezomib, Fulvestrant, Laboratory Biomarker Analysis
- Where
- 21 sites in United States
- Volunteers
- 118 people
- Sponsor
- National Cancer Institute (NCI)
Estrogen Receptor-negative Breast Cancer, Male Breast Cancer
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
This phase II trial is studying saracatinib to see how well it works in treating patients with metastatic or locally advanced breast cancer that cannot be removed by surgery.
- Conditions
- Estrogen Receptor-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00559507
- Testing
- saracatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
This randomized phase III trial studies two different schedules of zoledronic acid to compare how well they work in reducing bone-related complications in patients with breast cancer, prostate cancer, or multiple myeloma that has…
- Conditions
- Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone
- Trial name
- NCT00869206
- Testing
- zoledronic acid
- Where
- 504 sites in United States, Puerto Rico
- Volunteers
- 1,822 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
The main objective of the trial is to compare Invasive Disease-Free Survival (IDFS) of patients randomised to treatment with adjuvant chemotherapy alone or to adjuvant chemotherapy with 1 year of bevacizumab.
- Trial name
- NCT00528567
- Testing
- Bevacizumab, Standard adjuvant chemotherapy
- Where
- 403 sites in United States, Argentina and 38 more
- Volunteers
- 2,591 people
- Sponsor
- Hoffmann-La Roche
Stage I Breast Cancer, Stage II Breast Cancer
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations.
- Conditions
- Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer
- Trial name
- NCT04584255
- Testing
- Niraparib, Dostarlimab
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Dana-Farber Cancer Institute
Sleep Disorder, Stage IA Breast Cancer
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
This randomized phase II trial studies how well brief behavioral therapy works in improving sleep disorders in patients with stage I-III breast cancer undergoing chemotherapy.
- Conditions
- Sleep Disorder, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT02002533
- Testing
- Brief Behavioral Therapy, Telephone-Based Intervention, Educational Intervention
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- Gary Morrow
Breast Cancer
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- SOLE (NCT00553410)
- Testing
- Letrozole
- Where
- 164 sites in United States, Australia and 18 more
- Volunteers
- 4,884 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help in learning how well chemotherapy works to kill breast cancer cells and allow doctors to plan better treatment.
- Trial name
- ISNA-Sein (NCT00462696)
- Testing
- Neoadjuvant chemotherapy
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Institut Bergonié
Triple Negative Breast Neoplasms
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants…
- Trial name
- NCT03036488
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 193 sites in United States, Australia and 19 more
- Volunteers
- 1,174 people
- Sponsor
- Merck Sharp & Dohme LLC
Estrogen Receptor Negative, Estrogen Receptor Positive
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
This randomized phase III trial studies the side effects and how well different chemotherapy regimens with or without bevacizumab work in treating patients with stage IIIC or stage IV breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT00785291
- Testing
- Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis
- Where
- 704 sites in United States, Puerto Rico
- Volunteers
- 799 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Breast, Inflammation
Hypofractionated Radiotherapy in Breast Cancer
As the number of breast cancer (BrCA) survivors has markedly increased, clinicians are now seeking to reduce treatment-related toxicities and inconveniences of treatment, namely the traditional 6 weeks of daily radiation…
- Trial name
- NCT03167359
- Testing
- Hypofractionated Simultaneous Integrated Boost Radiotherapy
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Emory University
Breast Neoplasms
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
To compare efficacy and safety of Sunitinib and Capecitabine in subjects with advanced breast cancer who failed both a taxane and an anthracycline chemotherapy regimen or failed with a taxane and for whom further anthracycline…
- Trial name
- NCT00373113
- Testing
- Capecitabine, Sunitinib malate
- Where
- 123 sites in Argentina, Australia and 21 more
- Volunteers
- 482 people
- Sponsor
- Pfizer
Metastatic Breast Cancer
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
This study was a Phase III, randomized, double-blind, placebo-controlled, multicenter international clinical trial conducted to investigate the use of pertuzumab in combination with trastuzumab and docetaxel as first-line…
- Trial name
- CLEOPATRA (NCT00567190)
- Testing
- Pertuzumab, Trastuzumab, Docetaxel
- Where
- 322 sites in United States, Argentina and 24 more
- Volunteers
- 808 people
- Sponsor
- Genentech, Inc.
Melanoma
Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Evaluate the antitumor activity of hu14.18-IL2 in the minimal residual disease setting. Evaluate the time to recurrence and overall survival of patients treated with hu14.18-IL2.
- Trial name
- NCT00590824
- Testing
- hu14.18-IL2
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00295893
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- City of Hope Medical Center
Stage IV Melanoma, Stage III Melanoma
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
This is a Phase I/Ib investigator-initiated open label of the combination of VESANOID and pembrolizumab treatment.
- Conditions
- Stage IV Melanoma, Stage III Melanoma, Advanced Melanoma
- Trial name
- NCT03200847
- Testing
- Pembrolizumab with All-Trans Retinoic Acid
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Colorado, Denver
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes…
- Trial name
- PATINA (NCT02947685)
- Testing
- palbociclib, trastuzumab, pertuzumab
- Where
- 108 sites in United States, Australia and 6 more
- Volunteers
- 518 people
- Sponsor
- Alliance Foundation Trials, LLC.
HER2-positive Breast Cancer, Breast Adenocarcinoma
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib.
- Conditions
- HER2-positive Breast Cancer, Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7
- Trial name
- NCT03094052
- Testing
- Neratinib, Trastuzumab, Loperamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, San Francisco